hsa-mir-1238: Hsa-mir-1238 is a down-regulated miRNA that has been studied in various types of cancer, including HER2+ breast cancer, melanoma, hepatocellular carcinoma, osteosarcoma, glioblastoma, and hepatocellular carcinoma [PMC7706137] [PMC7706137] [PMC7706137] [PMC7706137]. It has been found to be associated with different tumor subtypes and stages of liver fibrosis [PMC7706137] [PMC7706137]. In breast tumor subtypes, hsa-mir-1238 has shown expression differences along with hsa-miR-365 and hsa-miR-184 [PMC9088870] [PMC9088870]. In a study on liver fibrosis stages, hsa-mir-1238 was found to be upregulated in the mild-severe fibrosis group and the significant liver fibrosis group [PMC7939739]. Diagnostic models using hsa-mir-1238 along with other miRNAs have been developed to predict significant hepatic fibrosis and have shown promising accuracy in identifying patients with different stages of liver fibrosis [PMC7939739]. Furthermore, a recent study reclassified hsa-mir-1238 mirtron in miRBase based on more stringent bioinformatic criteria applied for mirtron evaluation [PMC4807562]. Overall, the downregulation of hsa-mir-1238 is associated with various types of cancer and liver fibrosis stages. Further research is needed to fully understand its role in these diseases.